Biogen Inc. (Nasdaq: BIIB) shared positive data from the 16-week cutaneous lupus erythematosus (CLE) portion of the Phase 2 LILAC study. The study evaluated the efficacy and safety of BIIB059, the data were presented at the European E-Congress of Rheumatology (EULAR) 2020.
“We are encouraged by the CLE results from the BIIB059 Phase 2 lupus study presented at the 2020 virtual EULAR congress,” said Nathalie Franchimont, M.D., Ph.D., vice president of the multiple sclerosis and immunology development unit at Biogen. “These data underscore our goal of delivering meaningful new therapies to people living with lupus, who currently have limited treatment options.”
The trial included 132 participants with active CLE who were randomized to receive either BIIB059 (at doses of 50, 100, or 150 mg) or a placebo treatment. After a 16-week trial period, all three groups receiving the experimental treatment benefited from statistically significant reductions in skin disease activity compared to those receiving the placebo.
For further information please click here.
